Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes (Q73562634)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

A Bousvaros

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A C Stevens

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

T B Strom

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

J Murphy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

J T Lamont

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 July 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

Digestive Diseases and Sciences

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

1542-1548

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9246061%20AND%20SRC:MED&resulttype=core&format=json

Gut mucosal lymphocytes in inflammatory bowel disease: isolation and preliminary functional characterization

5 November 2019

cites work

1 reference

12 December 2020

Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease

1 reference

12 December 2020

Immune activation genes in inflammatory bowel disease

1 reference

12 December 2020

Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR)

1 reference

12 December 2020

Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study

1 reference

12 December 2020

Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens

1 reference

12 December 2020

Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia

1 reference

12 December 2020

Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells

1 reference

12 December 2020

T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells

1 reference

12 December 2020

Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones

1 reference

12 December 2020

Structure/function analysis of the transmembrane domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic dom

1 reference

12 December 2020

Advances in drug therapy for inflammatory bowel disease

1 reference

12 December 2020

Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers

1 reference

12 December 2020

Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis

1 reference

12 December 2020

The IL-2/IL-2 receptor system: a current overview

1 reference

12 December 2020

The role of the mucosal immune system in inflammatory bowel disease

1 reference

12 December 2020

Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis

1 reference

12 December 2020

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

12 December 2020

Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers

1 reference

12 December 2020

Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.

1 reference

12 December 2020

Preliminary report: cyclosporin in treatment of severe active ulcerative colitis

1 reference

12 December 2020

Soluble interleukin-2 receptor as a marker of lymphocyte activation in childhood Crohn's disease

1 reference

12 December 2020

Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules

1 reference

12 December 2020

Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein

1 reference

12 December 2020

Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma

1 reference

12 December 2020

Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia

1 reference

12 December 2020

Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor

1 reference

12 December 2020

Isolation and functional characterization of human intestinal mucosal lymphoid cells

1 reference

12 December 2020

Molecular evidence for two forms of Crohn disease

1 reference

12 December 2020

Interleukin-2: inception, impact, and implications

1 reference

12 December 2020

Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.

1 reference

12 December 2020

DAB486IL-2 fusion toxin in refractory rheumatoid arthritis

1 reference

12 December 2020

The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197.

1 reference

12 December 2020

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

12 December 2020

Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy

1 reference

12 December 2020